Prevents bronchospasm. ANDA 219409, held by Cipla. Albuterol Sulfate.
As of Nov 16, 2026, ANDA 219409 (Albuterol Sulfate), held by Cipla, was first approved by FDA on Apr 22, 2026, with 0 approved supplements and 0 published complete response letters.
Albuterol sulfate inhalation aerosol is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. Prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older. 1.1 Bronchospasm Albuterol sulfate inhalation aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2026 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.09MG BASE/INH · aerosol, metered;inhalation | Albuterol Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters